We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$8.89B
AUM Growth
+$1.45B
Cap. Flow
+$1.09B
Cap. Flow %
12.29%
Top 10 Hldgs %
26.12%
Holding
266
New
39
Increased
114
Reduced
52
Closed
27

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$63.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$50M
3
VR
Validus Hold Ltd
VR
+$44.1M
4
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.4M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$59.3M
2
DHR icon
Danaher
DHR
+$44.2M
3
HOLX
Hologic
HOLX
+$42M
4
BDX icon
Becton Dickinson
BDX
+$40.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$38.7M

Sector Composition

Rank Sector Weight
1 Financials 21.97%
2 Healthcare 21.33%
3 Technology 19.13%
4 Communication Services 9.13%
5 Industrials 6.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRA
126
DELISTED
ProAssurance
PRA
$20.2M 0.23%
370,000
+18,900
+5% +$1.07M
TLND
127
DELISTED
Talend S.A. American Depositary Shares
TLND
$19.8M 0.22%
485,007
-194,853
-29% -$7.51M
MRK icon
128
Merck
MRK
$324B
$19.5M 0.22%
318,871
– –
AFL icon
129
Aflac
AFL
$63.9B
$18.7M 0.21%
459,500
+9,400
+2% +$379K
BDX icon
130
Becton Dickinson
BDX
$43.1B
$18M 0.2%
93,989
-210,125
-69% -$40.7M
AVGO icon
131
Broadcom
AVGO
$1.82T
$17.9M 0.2%
737,550
+128,360
+21% +$3.17M
VRTX icon
132
Vertex Pharmaceuticals
VRTX
$121B
$17.7M 0.2%
116,500
+66,500
+133% +$10M
RLI icon
133
RLI Corp
RLI
$5.68B
$17.3M 0.19%
601,800
+10,000
+2% +$275K
AXS icon
134
AXIS Capital
AXS
$8.59B
$17.2M 0.19%
300,000
+45,000
+18% +$2.78M
HRTG icon
135
Heritage Insurance Holdings
HRTG
$842M
$17.2M 0.19%
1,300,000
+292,000
+29% +$3.51M
QTNT
136
DELISTED
Quotient Limited Ordinary Shares
QTNT
$16.5M 0.19%
83,829
+9,329
+13% +$1.86M
ANSS
137
DELISTED
Ansys
ANSS
$15.9M 0.18%
129,709
-3,691
-3% -$463K
UBS icon
138
UBS Group
UBS
$170B
$15.9M 0.18%
918,497
+353,728
+63% +$6.05M
MTSI icon
139
MACOM Technology Solutions
MTSI
$20.4B
$15.9M 0.18%
355,622
-22,078
-6% -$1.08M
DHR icon
140
Danaher
DHR
$135B
$15.7M 0.18%
205,928
-597,840
-74% -$44.2M
HCA icon
141
HCA Healthcare
HCA
$84.8B
$15.4M 0.17%
194,000
-6,908
-3% -$556K
AVEO
142
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$15.1M 0.17%
+412,924
New +$12.8M
CLDR
143
DELISTED
Cloudera, Inc.
CLDR
$15M 0.17%
+901,515
New +$16.1M
BIIB icon
144
Biogen
BIIB
$29.9B
$14.9M 0.17%
47,500
+17,500
+58% +$5.18M
CRTO icon
145
Criteo
CRTO
$1.03B
$14M 0.16%
336,314
-203,087
-38% -$9.68M
TD icon
146
Toronto Dominion Bank
TD
$198B
$13.7M 0.15%
218,255
+36,814
+20% +$1.93M
SUPN icon
147
Supernus Pharmaceuticals
SUPN
$2.68B
$13.6M 0.15%
338,956
+218,956
+182% +$9.48M
LIVN icon
148
LivaNova
LIVN
$4.3B
$13.4M 0.15%
+191,219
New +$12.1M
PNC icon
149
PNC Financial Services
PNC
$100B
$12.8M 0.14%
95,367
+21,367
+29% +$2.74M
FRC
150
DELISTED
First Republic Bank
FRC
$12.4M 0.14%
118,610
+17,892
+18% +$1.78M
4 5
6
7 8

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Polar Capital held 266 positions worth $8.89B, up 20% from $7.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Polar Capital deployed $1.09B of net new capital in Q3 2017, opening 39 new positions and adding to 114 existing holdings. Its largest new stake was Puma Biotechnology: 360,000 shares worth $43.1M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Medtronic, an estimated $59.3M trimmed.

  • Polar Capital's largest Q3 2017 buy was Puma Biotechnology: 360,000 shares worth $43.1M.
  • Polar Capital added most to Amgen in Q3 2017, an estimated $63.8M increase.
  • Polar Capital's biggest Q3 2017 reduction was Medtronic, cutting an estimated $59.3M.
  • Polar Capital fully exited Hologic in Q3 2017, selling an estimated $42M.
  • Polar Capital's ten largest holdings make up 26% of its $8.89B portfolio in Q3 2017.
  • Polar Capital opened 39 new positions and closed 27 in Q3 2017.
  • Polar Capital's portfolio value rose 20% quarter-over-quarter to $8.89B.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.